Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Options for postremission therapy in acute leukemia.

D Wujcik

    Seminars in Oncology Nursing
    |February 1, 1990
    PubMed
    Summary

    Achieving remission in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) is possible with induction therapy. Postremission strategies, including chemotherapy and bone marrow transplant (BMT), significantly improve long-term survival for AML patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Why do you do it that way?

    ONS news·2001
    Same author

    The National Cancer Program.

    Seminars in oncology nursing·2000
    Same author

    The Clinical Trials Office as a shared resource.

    Oncology nursing forum·2000
    Same author

    Development of a short version of the Barriers Questionnaire.

    Journal of pain and symptom management·1998
    Same author

    Future considerations in transplantation.

    Seminars in oncology nursing·1997
    Same author

    Update on the diagnosis of and therapy for acute promyelocytic leukemia and chronic myelogenous leukemia.

    Oncology nursing forum·1996

    Area of Science:

    • Hematology
    • Oncology
    • Clinical Medicine

    Background:

    • Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are aggressive blood cancers requiring intensive treatment.
    • Induction therapy aims to achieve remission, a critical first step in treatment.
    • Postremission therapy is essential for prolonging disease-free survival (DFS) in AML patients.

    Purpose of the Study:

    • To review the efficacy of induction and postremission therapies for AML and ALL.
    • To highlight the role of chemotherapy and bone marrow transplantation (BMT) in postremission care.
    • To emphasize the importance of patient support during treatment decisions.

    Main Methods:

    • Review of induction therapy success rates for AML and ALL.
    • Analysis of postremission therapy strategies in AML, including chemotherapy and BMT.
    • Discussion of maintenance therapy duration and BMT indications in ALL.

    Main Results:

    • Induction therapy achieves a 65%-75% complete remission (CR) rate in AML.
    • Postremission therapy increases prolonged DFS in AML to over 60%.
    • Induction therapy for ALL yields a 70%-75% CR rate, with maintenance therapy for 2-3 years.

    Conclusions:

    • Postremission therapy is crucial for improving long-term outcomes in AML.
    • BMT is a key consideration for high-risk or relapsed ALL patients.
    • Patient education and emotional support are vital for navigating complex treatment choices.

    Related Experiment Videos